Double-Dose transplant strategy shows promise for myeloma patients
NCT ID NCT01241708
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested a two-step (tandem) stem cell transplant in 148 people with multiple myeloma. Patients received high-dose melphalan chemotherapy, followed by a second transplant with melphalan plus bortezomib (Velcade). The goal was to see if this approach could delay cancer progression. The trial is complete, and results help guide future treatment options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Melphalan and Bortezomib (Velcade)
What this could lead to
If successful, this approach could extend the time patients with multiple myeloma live without their cancer worsening.
What could go wrong
This is a completed phase 3 trial, but results may not apply to all patients. High-dose chemotherapy carries risks like infection and organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
John Theurer Cancer Center @ Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States